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Background
The Cancer Immunotherapy Trials Network (CITN) is
conducting a pilot study in patients with advanced
epithelial ovarian, fallopian tube or primary peritoneal
carcinoma to determine the extent to which a regimen of
an IDO1 inhibitor that normalizes Kyn/Trp ratios might
be immunotherapeutic and alter the tumor microenviron-
ment, including the number and character of tumor infil-
trating lymphocyte and the gene signature of infiltrating
cells (PI: Kunle Odunsi). Here we describe preliminary
comparative analyses of NanoString’s nCounter gene
expression technology, IHC (PhenoPath) and Flow cyto-
metry (CITN Immune Monitoring Laboratory) using
FFPE slides and PBMCs from treated subjects.
Methods
Tumor biopsies, whole blood and Ficoll-gradient purified
PBMCs were collected from study subjects at multiple
study time-points. All subjects were treated for 2 weeks
(Day 1 through D14) with IDO1 inhibitor, INCB024360
(Incyte). The number and percentage of PBMC subsets
and T lymphocyte subsets were evaluated by multipara-
meter flow cytometry. Tumor biopsies were scored for
lymphocyte (CD3 and CD8) infiltration by standard IHC.
Gene expression from both PBMC and FFPE biopsies
were evaluated using the nCounter PanCancer Immune
Profiling panel that interrogates 770 immune-related
genes and associated controls using ~60,000 cell lysates
for PBMC and 300ng of total extracted RNA from
4-micron FFPE sections from tumor biopsies.
Results
IHC identified differential degrees (high, moderate, low) of
lymphocyte infiltration in FFPE biopsies. A strong correla-
tion to IHC results was observed in nCounter RNA-based
gene expression of neighboring FFPE sections. The major-
ity of PBMC and T lymphocyte subsets measured by flow
also trended positively with gene-expression data, both
across study participants and across collection time-points
for each patient. In addition to correlative association with
flow and IHC, gene expression profiling identified many
differentially expressed targets between trial subjects and
across trial time-points.
Conclusions
These data establish the nCounter PanCancer Immune
Profiling panel as a valuable investigative tool in immu-
notherapy trials. The strong correlative associations
between protein expression by flow and IHC with gene
expression profiling by nCounter PanCancer Immune
Profiling or other methods may ultimately expedite the
identification of vital and clinically relevant biomarkers.
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